Generic Sensipar Availability

Sensipar is a brand name of cinacalcet, approved by the FDA in the following formulation(s):

SENSIPAR (cinacalcet hydrochloride - tablet;oral)

  • Manufacturer: AMGEN
    Approval date: March 8, 2004
    Strength(s): EQ 30MG BASE, EQ 60MG BASE, EQ 90MG BASE [RLD]

Has a generic version of Sensipar been approved?

No. There is currently no therapeutically equivalent version of Sensipar available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Sensipar. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Calcium receptor-active molecules
    Patent 6,011,068
    Issued: January 4, 2000
    Inventor(s): Nemeth; Edward F. & Van Wagenen; Bradford C. & Balandrin; Manuel F. & DelMar; Eric G. & Moe; Scott T.
    Assignee(s): NPS Pharmaceuticals, Inc. The Brigham and Women's Hospital
    The present invention relates to the different roles inorganic ion receptors have in cellular and body processes. The present invention features: (1) molecules which can modulate one or more inorganic ion receptor activities, preferably the molecule can mimic or block an effect of an extracellular ion on a cell having an inorganic ion receptor, more preferably the extracellular ion is Ca.sup.2+ and the effect is on a cell having a calcium receptor; (2) inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (3) nucleic acids encoding inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (4) antibodies and fragments thereof, targeted to inorganic ion receptor proteins, preferably calcium receptor protein; and (5) uses of such molecules, proteins, nucleic acids and antibodies.
    Patent expiration dates:
    • March 8, 2018
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Calcium receptor-active molecules
    Patent 6,031,003
    Issued: February 29, 2000
    Inventor(s): Nemeth; Edward F. & Van Wagenen; Bradford C. & Balandrin; Manuel F. & DelMar; Eric G. & Moe; Scott T.
    Assignee(s): NPS Pharmaceuticals, Inc. The Brigham and Women's Hospital
    The present invention relates to the different roles inorganic ion receptors have in cellular and body processes. The present invention features: (1) molecules which can modulate one or more inorganic ion receptor activities, preferably the molecule can mimic or block an effect of an extracellular ion on a cell having an inorganic ion receptor, more preferably the extracellular ion is Ca.sup.2+ and the effect is on a cell having a calcium receptor; (2) inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (3) nucleic acids encoding inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (4) antibodies and fragments thereof, targeted to inorganic ion receptor proteins, preferably calcium receptor protein; and (5) uses of such molecules, proteins, nucleic acids and antibodies.
    Patent expiration dates:
    • December 14, 2016
      ✓ 
      Patent use: METHOD OF DECREASING OR REDUCING PARATHYROID HORMONE LEVEL; METHOD OF MODULATING PARATHYROID HORMONE SECRETION;METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF REDUCING SERUM IONIZED CALCIUM LEVEL
    • December 14, 2016
  • Calcium receptor-active compounds
    Patent 6,211,244
    Issued: April 3, 2001
    Inventor(s): Van Wagenen; Bradford C. & Moe; Scott T. & Balandrin; Manuel F. & DelMar; Eric G. & Nemeth; Edward F.
    Assignee(s): NPS Pharmaceuticals, Inc.
    The present invention features compounds able to modulate one or more activities of an inorganic ion receptor and methods for treating diseases or disorders by modulating inorganic ion receptor activity. Preferably, the compound can mimic or block the effect of extracellular Ca.sup.2+ on a calcium receptor.
    Patent expiration dates:
    • October 23, 2015
      ✓ 
      Patent use: METHOD OF DECREASING PARATHYROID HORMONE LEVEL;METHOD OF TREATING HYPERPARATHYROIDISM
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Calcium receptor-active molecules
    Patent 6,313,146
    Issued: November 6, 2001
    Inventor(s): Van Wagenen; Bradford C. & Balandrin; Manuel F. & DelMar; Eric G. & Nemeth; Edward F.
    Assignee(s): NPS Pharmaceuticals, Inc.
    The present invention relates to the different roles inorganic ion receptors have in cellular and body processes. The present invention features: (1) molecules which can modulate one or more inorganic ion receptor activities, preferably the molecule can mimic or block an effect of an extracellular ion on a cell having an inorganic ion receptor, more preferably the extracellular ion is Ca.sup.2+ and the effect is on a cell having a calcium receptor; (2) inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (3) nucleic acids encoding inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (4) antibodies and fragments thereof, targeted to inorganic ion receptor proteins, preferably calcium receptor protein; and (5) uses of such molecules, proteins, nucleic acids and antibodies.
    Patent expiration dates:
    • December 14, 2016
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Rapid dissolution formulation of a calcium receptor-active compound
    Patent 7,829,595
    Issued: November 9, 2010
    Inventor(s): Lawrence; Glen Gary & Alvarez; Francisco J. & Lin; Hung-Ren H. & Ju; Tzuchi R.
    Assignee(s): Amgen Inc.
    The present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of a calcium receptor-active compound and at least one pharmaceutically acceptable excipient, wherein the composition has a controlled dissolution profile. The present invention further relates to a method of manufacturing the pharmaceutical composition, as well as a method of treating a disease using the pharmaceutical composition.
    Patent expiration dates:
    • September 22, 2026
      ✓ 
      Patent use: METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • February 25, 2014 - TREATMENT OF SEVERE HYPERCALCEMIA IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM WHO ARE UNABLE TO UNDERGO PARATHYROIDECTOMY
    • February 25, 2014 - INCLUSION OF DATA FROM AN ADDITIONAL 19 SUBJECTS WITH HYPERCALCEMIA FROM PARATHYROID CARCINOMA TO THE INFORMATION CURRENTLY PRESENTED IN THE LABEL
    • February 25, 2018 -

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web2)